AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. EW
  4. [Form 4] Edwards Lifesciences Corp Insider Trading Activity

[Form 4] Edwards Lifesciences Corp Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Edwards Lifesciences (EW) Form 4 filing: Corporate Vice-President Annette Bruls reported one transaction on 07/11/2025. A total of 109 shares of common stock were withheld for tax purposes (Transaction Code F) at a price of $78.80 per share. Following the withholding, Bruls directly owns 14,171 EW shares. No derivative security activity or additional transactions were disclosed. The filing reflects routine administrative share withholding rather than an open-market sale.

Edwards Lifesciences (EW) Deposito Form 4: La Vicepresidente aziendale Annette Bruls ha segnalato una transazione il 11/07/2025. Un totale di 109 azioni ordinarie sono state trattenute a fini fiscali (Codice Transazione F) al prezzo di 78,80 $ per azione. Dopo la trattenuta, Bruls possiede direttamente 14.171 azioni EW. Non sono state divulgate attivit脿 su strumenti derivati o ulteriori transazioni. Il deposito riflette una normale trattenuta amministrativa delle azioni e non una vendita sul mercato aperto.

Presentaci贸n del Formulario 4 de Edwards Lifesciences (EW): La Vicepresidenta Corporativa Annette Bruls inform贸 una transacci贸n el 11/07/2025. Se retuvieron un total de 109 acciones comunes para fines fiscales (C贸digo de Transacci贸n F) a un precio de 78,80 $ por acci贸n. Tras la retenci贸n, Bruls posee directamente 14,171 acciones de EW. No se revelaron actividades con valores derivados ni transacciones adicionales. La presentaci贸n refleja una retenci贸n administrativa rutinaria de acciones, no una venta en el mercado abierto.

Edwards Lifesciences (EW) Form 4 鞝滌稖: 旮办梾 攵�靷灔 Annette Bruls臧� 2025雲� 7鞗� 11鞚检棎 頃� 瓯挫潣 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 齑� 109欤检潣 氤错喌欤缄皜 靹戈笀 氇╈爜鞚� 鞙勴暣 鞗愳矞歆曥垬霅橃棃鞙茧┌(瓯半灅 旖旊摐 F), 欤茧嫻 臧�瓴╈潃 78.80雼煬鞓�鞀惦媹雼�. 鞗愳矞歆曥垬 頉� Bruls電� 歆侅爲 14,171欤� EW 欤检嫕鞚� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 韺岇儩靸來拡 甏�霠� 頇滊彊鞚措倶 於旉皜 瓯半灅電� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�. 鞚措矆 鞝滌稖鞚� 瓿店皽 鞁滌灔鞐愳劀鞚� 毵る弰臧� 鞎勲媽 鞚检儊鞝侅澑 頄夓爼鞝� 欤检嫕 鞗愳矞歆曥垬毳� 氚橃榿頃╇媹雼�.

D茅p么t du Formulaire 4 d'Edwards Lifesciences (EW) : La vice-pr茅sidente d'entreprise Annette Bruls a d茅clar茅 une transaction le 11/07/2025. Un total de 109 actions ordinaires ont 茅t茅 retenues 脿 des fins fiscales (Code de transaction F) au prix de 78,80 $ par action. Apr猫s cette retenue, Bruls d茅tient directement 14 171 actions EW. Aucune activit茅 sur instruments d茅riv茅s ni transaction suppl茅mentaire n鈥檃 茅t茅 divulgu茅e. Le d茅p么t refl猫te une retenue administrative courante d鈥檃ctions plut么t qu鈥檜ne vente sur le march茅 ouvert.

Edwards Lifesciences (EW) Form 4 Einreichung: Die Corporate Vice-President Annette Bruls meldete am 11.07.2025 eine Transaktion. Insgesamt wurden 109 Stammaktien steuerlich einbehalten (Transaktionscode F) zu einem Preis von 78,80 $ pro Aktie. Nach dem Einbehalt besitzt Bruls direkt 14.171 EW-Aktien. Es wurden keine Aktivit盲ten mit Derivaten oder weitere Transaktionen offengelegt. Die Einreichung spiegelt eine routinem盲脽ige administrative Aktieneinbehaltung wider und keinen Verkauf am offenen Markt.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine tax withholding of 109 shares; negligible impact on EW.

This Form 4 shows a Code F disposition鈥攕hares surrendered to cover taxes on vesting equity. The 109 shares involved represent less than 1% of the insider鈥檚 14,171-share holding and an immaterial fraction of EW鈥檚 614 million shares outstanding. There is no indication of bearish sentiment or strategic shift; therefore, the market impact is expected to be neutral.

Edwards Lifesciences (EW) Deposito Form 4: La Vicepresidente aziendale Annette Bruls ha segnalato una transazione il 11/07/2025. Un totale di 109 azioni ordinarie sono state trattenute a fini fiscali (Codice Transazione F) al prezzo di 78,80 $ per azione. Dopo la trattenuta, Bruls possiede direttamente 14.171 azioni EW. Non sono state divulgate attivit脿 su strumenti derivati o ulteriori transazioni. Il deposito riflette una normale trattenuta amministrativa delle azioni e non una vendita sul mercato aperto.

Presentaci贸n del Formulario 4 de Edwards Lifesciences (EW): La Vicepresidenta Corporativa Annette Bruls inform贸 una transacci贸n el 11/07/2025. Se retuvieron un total de 109 acciones comunes para fines fiscales (C贸digo de Transacci贸n F) a un precio de 78,80 $ por acci贸n. Tras la retenci贸n, Bruls posee directamente 14,171 acciones de EW. No se revelaron actividades con valores derivados ni transacciones adicionales. La presentaci贸n refleja una retenci贸n administrativa rutinaria de acciones, no una venta en el mercado abierto.

Edwards Lifesciences (EW) Form 4 鞝滌稖: 旮办梾 攵�靷灔 Annette Bruls臧� 2025雲� 7鞗� 11鞚检棎 頃� 瓯挫潣 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 齑� 109欤检潣 氤错喌欤缄皜 靹戈笀 氇╈爜鞚� 鞙勴暣 鞗愳矞歆曥垬霅橃棃鞙茧┌(瓯半灅 旖旊摐 F), 欤茧嫻 臧�瓴╈潃 78.80雼煬鞓�鞀惦媹雼�. 鞗愳矞歆曥垬 頉� Bruls電� 歆侅爲 14,171欤� EW 欤检嫕鞚� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 韺岇儩靸來拡 甏�霠� 頇滊彊鞚措倶 於旉皜 瓯半灅電� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�. 鞚措矆 鞝滌稖鞚� 瓿店皽 鞁滌灔鞐愳劀鞚� 毵る弰臧� 鞎勲媽 鞚检儊鞝侅澑 頄夓爼鞝� 欤检嫕 鞗愳矞歆曥垬毳� 氚橃榿頃╇媹雼�.

D茅p么t du Formulaire 4 d'Edwards Lifesciences (EW) : La vice-pr茅sidente d'entreprise Annette Bruls a d茅clar茅 une transaction le 11/07/2025. Un total de 109 actions ordinaires ont 茅t茅 retenues 脿 des fins fiscales (Code de transaction F) au prix de 78,80 $ par action. Apr猫s cette retenue, Bruls d茅tient directement 14 171 actions EW. Aucune activit茅 sur instruments d茅riv茅s ni transaction suppl茅mentaire n鈥檃 茅t茅 divulgu茅e. Le d茅p么t refl猫te une retenue administrative courante d鈥檃ctions plut么t qu鈥檜ne vente sur le march茅 ouvert.

Edwards Lifesciences (EW) Form 4 Einreichung: Die Corporate Vice-President Annette Bruls meldete am 11.07.2025 eine Transaktion. Insgesamt wurden 109 Stammaktien steuerlich einbehalten (Transaktionscode F) zu einem Preis von 78,80 $ pro Aktie. Nach dem Einbehalt besitzt Bruls direkt 14.171 EW-Aktien. Es wurden keine Aktivit盲ten mit Derivaten oder weitere Transaktionen offengelegt. Die Einreichung spiegelt eine routinem盲脽ige administrative Aktieneinbehaltung wider und keinen Verkauf am offenen Markt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bruls Annette
(Last) (First) (Middle)
ONE EDWARDS WAY
(Street)
IRVINE CA 92614
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CVP, EMEACLA
3. Date of Earliest Transaction (Month/Day/Year)
07/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/11/2025 F 109 D $78.8 14,171 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
Linda J. Park, Attorney-in-Fact 07/11/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many Edwards Lifesciences (EW) shares did Annette Bruls dispose of?

The filing shows 109 shares were withheld for taxes on 07/11/2025.

What transaction code was reported in the EW Form 4?

The transaction was marked Code F, indicating shares withheld to satisfy tax obligations.

How many EW shares does the insider now own?

After the transaction, Annette Bruls directly owns 14,171 shares of Edwards Lifesciences.

Was there any derivative security activity reported?

No; Table II shows no acquisitions or dispositions of derivative securities.

Does this Form 4 suggest a change in insider sentiment at EW?

The small, tax-related share withholding is routine and does not imply a strategic change or negative outlook.
Stock EW logo
Edwards Lifesciences Corp

NYSE:EW

EW Rankings

#444 Ranked by Market Cap
N/A Ranked by Dividends

EW Latest News

Jul 18, 2025
Edwards Lifesciences to Host Earnings Conference Call on July 24, 2025
May 22, 2025
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes
May 6, 2025
Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference
May 1, 2025
Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis
Apr 23, 2025
Edwards Lifesciences Reports First Quarter Results

EW Latest SEC Filings

Jul 7, 2025
[Form 4] Edwards Lifesciences Corp Insider Trading Activity

EW Stock Data

46.22B
579.61M
0.91%
88.97%
1.44%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
United States
IRVINE